Depomed Inc. (NASDAQ:DEPO) has been given a $27.00 price target by equities research analysts at Roth Capital in a research note issued on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Roth Capital’s price objective would indicate a potential upside of 33.00% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Leerink Swann set a $22.00 target price on Depomed and gave the company a “buy” rating in a research note on Tuesday, November 8th. Mizuho upgraded Depomed from a “neutral” rating to a “buy” rating and decreased their target price for the company from $27.00 to $24.00 in a research note on Wednesday, November 9th. They noted that the move was a valuation call. Cantor Fitzgerald cut Depomed from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $23.00 in a report on Tuesday, November 8th. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $31.00 price target on shares of Depomed in a report on Monday, October 17th. Finally, RBC Capital Markets reaffirmed a “sector perform” rating and issued a $22.00 price target on shares of Depomed in a report on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $22.99.

Analyst Recommendations for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) traded up 0.663% on Monday, reaching $19.901. The company had a trading volume of 471,328 shares. The stock’s market cap is $1.23 billion. Depomed has a one year low of $12.25 and a one year high of $27.02. The company has a 50-day moving average of $22.27 and a 200 day moving average of $21.13.

Depomed (NASDAQ:DEPO) last announced its earnings results on Monday, November 7th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.35 by $0.07. Depomed had a negative net margin of 16.93% and a negative return on equity of 7.49%. The business had revenue of $111 million for the quarter, compared to the consensus estimate of $127.22 million. During the same quarter in the previous year, the company earned $0.33 EPS. Depomed’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, equities research analysts predict that Depomed will post $1.04 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international copyright laws. The legal version of this piece of content can be read at http://www.dailypolitical.com/2016/11/29/depomed-inc-depo-given-a-27-00-price-target-at-roth-capital.html.

In related news, VP Thadd M. Vargas sold 11,250 shares of the stock in a transaction that occurred on Wednesday, September 21st. The stock was sold at an average price of $25.00, for a total transaction of $281,250.00. Following the sale, the vice president now directly owns 73,086 shares in the company, valued at approximately $1,827,150. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO August J. Moretti sold 5,000 shares of the stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $20.84, for a total value of $104,200.00. Following the sale, the chief financial officer now owns 26,680 shares in the company, valued at $556,011.20. The disclosure for this sale can be found here. Corporate insiders own 5.12% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Depomed by 197.5% in the second quarter. BlackRock Inc. now owns 5,137 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,410 shares during the period. Acadian Asset Management LLC acquired a new stake in Depomed during the third quarter worth approximately $120,000. PineBridge Investments L.P. raised its stake in Depomed by 4.1% in the second quarter. PineBridge Investments L.P. now owns 7,748 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 306 shares during the period. DIAM Co. Ltd. acquired a new stake in Depomed during the second quarter worth approximately $157,000. Finally, Teacher Retirement System of Texas raised its stake in Depomed by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 8,482 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 1,024 shares during the period.

About Depomed

5 Day Chart for NASDAQ:DEPO

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.